ONCWF (Oncolytics Biotech) Additional Paid-In Capital : $30.93 Mil(As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Oncolytics Biotech Additional Paid-In Capital?

Oncolytics Biotech's quarterly additional paid-in capital declined from Sep. 2024 ($32.22 Mil) to Dec. 2024 ($31.26 Mil) but then stayed the same from Dec. 2024 ($31.26 Mil) to Mar. 2025 ($30.93 Mil).

Oncolytics Biotech's annual additional paid-in capital increased from Dec. 2022 ($29.48 Mil) to Dec. 2023 ($31.39 Mil) but then declined from Dec. 2023 ($31.39 Mil) to Dec. 2024 ($31.26 Mil).

Oncolytics Biotech Additional Paid-In Capital Historical Data

The historical data trend for Oncolytics Biotech's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech Additional Paid-In Capital Chart

Oncolytics Biotech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

24.22

26.69

29.48

31.39

31.26

Oncolytics Biotech Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															31.54	31.52	32.22	31.26	30.93

Oncolytics Biotech Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Oncolytics Biotech Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncolytics Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (OTCPK:ONCWF) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

ONCY:USA ONC:Canada

Address

322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5

Website

https://www.oncolyticsbiotech.com

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.